Course InformationTherapautic Area: Pulmonolgy
Format(s): Meeting Reporter, Downloadable Transcript
Credit(s): 1.0 AMA PRA Category 1 Credit(s)™
Activity Dates: December 6, 2016-December 5, 2017
This CME program focuses on content presented during the CHEST 2016 Annual Meeting in Los Angeles, California on October 22 – 26, 2016 and will address clinical decision-making for the management of patients with asthma. The expert faculty of this program will discuss conference highlights as well as the most comprehensive analysis for clinical decision-making in patients with asthma. They will discuss the effectiveness of communicating therapeutic decisions with patients. This program will give physicians a better understanding of when to implement data-driven, patient-specific treatment plans to improve outcomes for patients with asthma.
Allergists/Immunologists, pulmonologists, primary care physicians, and other healthcare clinicians responsible for the care of patients with asthma.
Upon completion of this activity, participants will be able to:
- Review the pathogenesis of asthma, including the role of biomarkers.
- Evaluate current and emerging targeted and biologic therapies for the treatment of moderate-to-severe asthma presented at CHEST 2016.
- Incorporate patient education into individualized treatment plans to improve patient adherence and overall quality of life for patients with moderate-to-severe asthma.
Reynold A. Panettieri, Jr, M.D.
Robert L. Mayock and David A. Cooper Professor of Medicine Director
Airways Biology Initiative Adjunct Professor
Wistar Institute Deputy Director
Center of Excellence in Environmental Toxicology
Perlman School of Medicine University of Pennsylvania Pulmonary
Allergy and Critical Care Division
Sidney Braman, MD
Professor of Medicine
Director, Pulmonary Disease Management
Division of Pulmonary Critical Care & Sleep Medicine
Ichan School of Medicine at Mount Sinai
New York, NY
This activity is expired for CE Credit
This Educational activity is co-provided by EOCME and ACME
This CME activity has been supported by an independent educational grant from Genentech, Inc. and Teva Pharmaceuticals